About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

STIM+: PET Biomarker Education & Disclosure | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNANCT04818255

STIM+: PET Biomarker Education & Disclosure

When dementia is caused by AD, we refer to it as dementia of the Alzheimer's Type (DAT). The greatest risk factor for Alzheimer's Disease (AD) and DAT is advancing age, but DAT is not a normal part of...

Lead sponsor: University of Michigan•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Michigan

Collaborators

National Institute on Aging (NIA)

Age

55 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Enrolled in the Stimulation to Improve Memory Study (NCT03875326).
•Completed PET scan with amyloid and/or tau tracer success.
•Demonstrates decision-making capacity to engage in PET disclosure, or has a care partner in attendance that demonstrates decision-making capacity for the participant to engage in disclosure
•If diagnosed with DAT: must have a cognitively intact study partner (i.e., their care partner)
•If diagnosed with MCI: strongly recommended to have a cognitively intact study partner (i.e., their care partner)

Exclusion Criteria

•Active diagnosis of moderate depression or anxiety without treatment
•Newly diagnosed neurologic disease (since completion of Stimulation to Improve Memory Study activities)

Related studies

A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses

NCT05877196 · Mild Cognitive Impairment, Alzheimer Disease, and more

Feasibility Study of 'SuperBrain BOOM' for Mild Cognitive Impairment Patients

NCT07101380 · Mild Cognitive Impairment (MCI)

The Swedish BioFINDER - Preclinical AD Study

NCT06121544 · Alzheimer Disease, Mild Cognitive Impairment, and more

Effects of Real vs. Soundless Acoustic Stimulation During Deep Sleep on Brain Activity, Memory, and Blood Biomarkers in Older Adults (60-85) With Mild Memory Impairment

NCT06669546 · Cognitive Decline, Alzheimer Disease, and more

China Cognition and Aging Study

NCT03653156 · Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 29, 2026Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment152

Start dateDec 2020

Last updatedJan 29, 2026

Condition

Mild Cognitive Impairment Dementia; Alzheimer's Type (Etiology)

Locations shown

University of Michigan Medical School, Department of Psychiatry

Ann Arbor, Michigan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 29, 2026Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions